

Carla Colombo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7523775/publications.pdf>

Version: 2024-02-01

40
papers

1,593
citations

411340

20
h-index

355658

38
g-index

40
all docs

40
docs citations

40
times ranked

2162
citing authors

#	ARTICLE	IF	CITATIONS
1	Improve knowledge and management of thyroid cancer: the role of the endocrinologist in a multidisciplinary team. <i>Minerva Medica</i> , 2022, 112, 689-691.	0.3	1
2	FAM83B is involved in thyroid cancer cell differentiation and migration. <i>Scientific Reports</i> , 2022, 12, .	1.6	0
3	Personalized treatment for differentiated thyroid cancer: current data and new perspectives. <i>Minerva Endocrinology</i> , 2021, 46, 62-89.	0.6	6
4	The thyroid risk score (TRS) for nodules with indeterminate cytology. <i>Endocrine-Related Cancer</i> , 2021, 28, 225-235.	1.6	12
5	Combined Mutational and Clonality Analyses Support the Existence of Intra-Tumor Heterogeneity in Papillary Thyroid Cancer. <i>Journal of Clinical Medicine</i> , 2021, 10, 2645.	1.0	3
6	<i>BRAF</i> V600E Status Sharply Differentiates Lymph Node Metastasis-associated Mortality Risk in Papillary Thyroid Cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 3228-3238.	1.8	36
7	Basal and Calcium-Stimulated Procalcitonin for the Diagnosis of Medullary Thyroid Cancers: Lights and Shadows. <i>Frontiers in Endocrinology</i> , 2021, 12, 754565.	1.5	9
8	<i>BRAF</i> V600E status may facilitate decision-making on active surveillance of low-risk papillary thyroid microcarcinoma. <i>European Journal of Cancer</i> , 2020, 124, 161-169.	1.3	41
9	The molecular and gene/miRNA expression profiles of radioiodine resistant papillary thyroid cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020, 39, 245.	3.5	27
10	Clinical and Genetic Features of a Large Monocentric Series of Familial Non-Medullary Thyroid Cancers. <i>Frontiers in Endocrinology</i> , 2020, 11, 589340.	1.5	8
11	Genetic variants of <i>PARP4</i> gene and <i>PARP4P2</i> pseudogene in patients with multiple primary tumors including thyroid cancer. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 2019, 816-818, 111672.	0.4	3
12	Impact of Mutation Density and Heterogeneity on Papillary Thyroid Cancer Clinical Features and Remission Probability. <i>Thyroid</i> , 2019, 29, 237-251.	2.4	31
13	<i>BRAF</i> V600E Mutation-Assisted Risk Stratification of Solitary Intrathyroidal Papillary Thyroid Cancer for Precision Treatment. <i>Journal of the National Cancer Institute</i> , 2018, 110, 362-370.	3.0	60
14	Circulating miR-375 as a novel prognostic marker for metastatic medullary thyroid cancer patients. <i>Endocrine-Related Cancer</i> , 2018, 25, 217-231.	1.6	50
15	MassARRAY-based simultaneous detection of hotspot somatic mutations and recurrent fusion genes in papillary thyroid carcinoma: the PTC-MA assay. <i>Endocrine</i> , 2018, 61, 36-41.	1.1	13
16	Letter regarding the article: "Multiple <i>HABP2</i> variants in familial papillary thyroid carcinoma: Contribution of a group of thyroid-checked controls" by Kern et al.. <i>European Journal of Medical Genetics</i> , 2018, 61, 104-105.	0.7	7
17	Patient Age-Associated Mortality Risk Is Differentiated by <i>BRAF</i> V600E Status in Papillary Thyroid Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 438-445.	0.8	102
18	<i>BRAF</i> V600E Confers Male Sex Disease-Specific Mortality Risk in Patients With Papillary Thyroid Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 2787-2795.	0.8	58

#	ARTICLE	IF	CITATIONS
19	Tumor and normal thyroid spheroids: from tissues to zebrafish. <i>Minerva Endocrinology</i> , 2018, 43, 1-10.	0.6	23
20	Segregation and expression analyses of hyaluronan-binding protein 2 (HABP2): insights from a large series of familial non-medullary thyroid cancers and literature review. <i>Clinical Endocrinology</i> , 2017, 86, 837-844.	1.2	13
21	The Prognostic Value of Tumor Multifocality in Clinical Outcomes of Papillary Thyroid Cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 3241-3250.	1.8	80
22	Multicellular spheroids from normal and neoplastic thyroid tissues as a suitable model to test the effects of multikinase inhibitors. <i>Oncotarget</i> , 2017, 8, 9752-9766.	0.8	14
23	Oxidative stress and the subcellular localization of the telomerase reverse transcriptase (TERT) in papillary thyroid cancer. <i>Molecular and Cellular Endocrinology</i> , 2016, 431, 54-61.	1.6	23
24	Differential Clinicopathological Risk and Prognosis of Major Papillary Thyroid Cancer Variants. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 264-274.	1.8	179
25	Basal and stimulated calcitonin levels in patients with type 2 diabetes did not change during 1 year of Liraglutide treatment. <i>Metabolism: Clinical and Experimental</i> , 2016, 65, 1-6.	1.5	17
26	Fetal cell microchimerism in papillary thyroid cancer: A role in the outcome of the disease. <i>International Journal of Cancer</i> , 2015, 137, 2989-2993.	2.3	12
27	Fetal cell microchimerism: a protective role in autoimmune thyroid diseases. <i>European Journal of Endocrinology</i> , 2015, 173, 111-118.	1.9	16
28	Impact of estrogen and progesterone receptor expression on the clinical and molecular features of papillary thyroid cancer. <i>European Journal of Endocrinology</i> , 2015, 173, 29-36.	1.9	60
29	The modifier role of RET-G691S polymorphism in hereditary medullary thyroid carcinoma: functional characterization and expression/penetrance studies. <i>Orphanet Journal of Rare Diseases</i> , 2015, 10, 25.	1.2	24
30	Telomerase in differentiated thyroid cancer: Promoter mutations, expression and localization. <i>Molecular and Cellular Endocrinology</i> , 2015, 399, 288-295.	1.6	100
31	Refining Calcium Test for the Diagnosis of Medullary Thyroid Cancer: Cutoffs, Procedures, and Safety. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 1656-1664.	1.8	98
32	Are pre-miR-146a and PTTG1 associated with papillary thyroid cancer?. <i>Endocrine Connections</i> , 2013, 2, 178-185.	0.8	13
33	Clinical and molecular analyses of thyroid cancer in patients treated for benign diseases. <i>Endocrine-Related Cancer</i> , 2013, 20, L7-L10.	1.6	1
34	Comparison of Calcium and Pentagastrin Tests for the Diagnosis and Follow-Up of Medullary Thyroid Cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 905-913.	1.8	95
35	Papillary Thyroid Carcinoma and Inflammation. <i>Frontiers in Endocrinology</i> , 2011, 2, 88.	1.5	15
36	Fetal cell microchimerism in papillary thyroid cancer: studies in peripheral blood and tissues. <i>International Journal of Cancer</i> , 2010, 126, 2874-2878.	2.3	35

#	ARTICLE	IF	CITATIONS
37	The tight relationship between papillary thyroid cancer, autoimmunity and inflammation: clinical and molecular studies. <i>Clinical Endocrinology</i> , 2010, 72, 702-708.	1.2	147
38	Clinical and molecular features of differentiated thyroid cancer diagnosed during pregnancy. <i>European Journal of Endocrinology</i> , 2010, 162, 145-151.	1.9	106
39	Outcome predictors and impact of central node dissection and radiometabolic treatments in papillary thyroid cancers. <i>Endocrine-Related Cancer</i> , 2009, 16, 201-210.	1.6	50
40	Unilateral Surgery for Medullary Thyroid Carcinoma: Seeking for Clinical Practice Guidelines. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	5